Annual SGA
$81.45 M
-$2.78 M-3.31%
December 31, 2023
Summary
- As of February 7, 2025, FATE annual SGA is $81.45 million, with the most recent change of -$2.78 million (-3.31%) on December 31, 2023.
- During the last 3 years, FATE annual SGA has risen by +$47.55 million (+140.29%).
- FATE annual SGA is now -3.31% below its all-time high of $84.23 million, reached on December 31, 2022.
Performance
FATE SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$20.80 M
+$3.55 M+20.58%
September 30, 2024
Summary
- As of February 7, 2025, FATE quarterly SGA is $20.80 million, with the most recent change of +$3.55 million (+20.58%) on September 30, 2024.
- Over the past year, FATE quarterly SGA has increased by +$1.85 million (+9.78%).
- FATE quarterly SGA is now -8.05% below its all-time high of $22.62 million, reached on June 30, 2023.
Performance
FATE Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$5.12 B
-$178.23 M-3.61%
September 30, 2024
Summary
- As of February 7, 2025, FATE TTM SGA is -$5.12 billion, with the most recent change of -$178.23 million (-3.61%) on September 30, 2024.
- Over the past year, FATE TTM SGA has dropped by -$5.20 billion (-6111.34%).
- FATE TTM SGA is now -7696.19% below its all-time high of -$65.61 million.
Performance
FATE TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
FATE Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.3% | +9.8% | -6111.3% |
| 3 y3 years | +140.3% | -5.2% | -6087.7% |
| 5 y5 years | +415.2% | +169.1% | -10000.0% |
FATE Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -3.3% | +42.1% | -8.1% | +22.8% | -87.5% | at low |
| 5 y | 5-year | -3.3% | +244.6% | -8.1% | +211.8% | -272.7% | at low |
| alltime | all time | -3.3% | +1826.4% | -8.1% | +2310.3% | -7696.2% | at low |
Fate Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $20.80 M(+20.6%) | $76.84 M(+2.5%) |
| Jun 2024 | - | $17.25 M(-17.3%) | $74.99 M(-6.7%) |
| Mar 2024 | - | $20.86 M(+16.3%) | $80.36 M(-1.3%) |
| Dec 2023 | $81.45 M(-3.3%) | $17.93 M(-5.3%) | $81.45 M(-4.3%) |
| Sep 2023 | - | $18.95 M(-16.2%) | $85.10 M(-3.0%) |
| Jun 2023 | - | $22.62 M(+3.1%) | $87.70 M(+2.7%) |
| Mar 2023 | - | $21.94 M(+1.7%) | $85.43 M(+1.4%) |
| Dec 2022 | $84.23 M(+46.9%) | $21.58 M(+0.1%) | $84.23 M(+5.8%) |
| Sep 2022 | - | $21.55 M(+5.9%) | $79.58 M(+7.9%) |
| Jun 2022 | - | $20.35 M(-1.9%) | $73.75 M(+12.5%) |
| Mar 2022 | - | $20.74 M(+22.5%) | $65.56 M(+14.4%) |
| Dec 2021 | $57.32 M(+69.1%) | $16.94 M(+7.7%) | $57.32 M(+13.1%) |
| Sep 2021 | - | $15.72 M(+29.2%) | $50.70 M(+17.0%) |
| Jun 2021 | - | $12.17 M(-2.7%) | $43.33 M(+12.1%) |
| Mar 2021 | - | $12.50 M(+21.2%) | $38.67 M(+14.1%) |
| Dec 2020 | $33.90 M(+43.4%) | $10.31 M(+23.5%) | $33.90 M(+12.0%) |
| Sep 2020 | - | $8.35 M(+11.3%) | $30.25 M(+7.1%) |
| Jun 2020 | - | $7.50 M(-2.9%) | $28.25 M(+8.6%) |
| Mar 2020 | - | $7.73 M(+15.9%) | $26.02 M(+10.1%) |
| Dec 2019 | $23.64 M(+49.5%) | $6.67 M(+5.1%) | $23.64 M(+11.1%) |
| Sep 2019 | - | $6.35 M(+20.4%) | $21.27 M(+11.9%) |
| Jun 2019 | - | $5.27 M(-1.5%) | $19.01 M(+8.3%) |
| Mar 2019 | - | $5.35 M(+24.2%) | $17.55 M(+11.0%) |
| Dec 2018 | $15.81 M | $4.31 M(+5.5%) | $15.81 M(+6.2%) |
| Sep 2018 | - | $4.08 M(+6.9%) | $14.88 M(+9.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | $3.82 M(+5.9%) | $13.59 M(+9.2%) |
| Mar 2018 | - | $3.60 M(+6.5%) | $12.45 M(+4.8%) |
| Dec 2017 | $11.87 M(+19.8%) | $3.38 M(+21.4%) | $11.87 M(+8.5%) |
| Sep 2017 | - | $2.79 M(+4.5%) | $10.94 M(+1.6%) |
| Jun 2017 | - | $2.67 M(-12.0%) | $10.76 M(+4.1%) |
| Mar 2017 | - | $3.03 M(+23.7%) | $10.34 M(+4.3%) |
| Dec 2016 | $9.91 M(-4.2%) | $2.45 M(-6.1%) | $9.91 M(-1.0%) |
| Sep 2016 | - | $2.61 M(+16.1%) | $10.02 M(+2.7%) |
| Jun 2016 | - | $2.25 M(-13.6%) | $9.76 M(-4.3%) |
| Mar 2016 | - | $2.60 M(+1.8%) | $10.20 M(-1.5%) |
| Dec 2015 | $10.35 M(+22.2%) | $2.56 M(+8.7%) | $10.35 M(+4.8%) |
| Sep 2015 | - | $2.35 M(-12.6%) | $9.88 M(+4.7%) |
| Jun 2015 | - | $2.69 M(-2.4%) | $9.43 M(+7.0%) |
| Mar 2015 | - | $2.76 M(+32.6%) | $8.81 M(+4.0%) |
| Dec 2014 | $8.47 M(+27.6%) | $2.08 M(+9.1%) | $8.47 M(+2.5%) |
| Sep 2014 | - | $1.90 M(-8.1%) | $8.26 M(-0.9%) |
| Jun 2014 | - | $2.07 M(-14.2%) | $8.34 M(+7.5%) |
| Mar 2014 | - | $2.42 M(+29.1%) | $7.76 M(+16.8%) |
| Dec 2013 | $6.64 M(+57.0%) | $1.87 M(-5.5%) | $6.64 M(+9.7%) |
| Sep 2013 | - | $1.98 M(+32.6%) | $6.05 M(+22.6%) |
| Jun 2013 | - | $1.49 M(+15.0%) | $4.94 M(+43.3%) |
| Mar 2013 | - | $1.30 M(+1.0%) | $3.44 M(+60.4%) |
| Dec 2012 | $4.23 M(-8.2%) | $1.28 M(+48.8%) | $2.15 M(+148.8%) |
| Sep 2012 | - | $863.00 K | $863.00 K |
| Dec 2011 | $4.61 M | - | - |
FAQ
- What is Fate Therapeutics annual SGA?
- What is the all time high annual SGA for Fate Therapeutics?
- What is Fate Therapeutics annual SGA year-on-year change?
- What is Fate Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Fate Therapeutics?
- What is Fate Therapeutics quarterly SGA year-on-year change?
- What is Fate Therapeutics TTM SGA?
- What is the all time high TTM SGA for Fate Therapeutics?
- What is Fate Therapeutics TTM SGA year-on-year change?
What is Fate Therapeutics annual SGA?
The current annual SGA of FATE is $81.45 M
What is the all time high annual SGA for Fate Therapeutics?
Fate Therapeutics all-time high annual SGA is $84.23 M
What is Fate Therapeutics annual SGA year-on-year change?
Over the past year, FATE annual SGA has changed by -$2.78 M (-3.31%)
What is Fate Therapeutics quarterly SGA?
The current quarterly SGA of FATE is $20.80 M
What is the all time high quarterly SGA for Fate Therapeutics?
Fate Therapeutics all-time high quarterly SGA is $22.62 M
What is Fate Therapeutics quarterly SGA year-on-year change?
Over the past year, FATE quarterly SGA has changed by +$1.85 M (+9.78%)
What is Fate Therapeutics TTM SGA?
The current TTM SGA of FATE is -$5.12 B
What is the all time high TTM SGA for Fate Therapeutics?
Fate Therapeutics all-time high TTM SGA is -$65.61 M
What is Fate Therapeutics TTM SGA year-on-year change?
Over the past year, FATE TTM SGA has changed by -$5.20 B (-6111.34%)